Frank Kelly, Jr. Appointed to InVasc Therapeutics Board of Directors
Published: Sep 20, 2010
ATLANTA--(BUSINESS WIRE)--InVasc Therapeutics, Inc., a biopharmaceutical company focused on chronic kidney and cardiometabolic diseases, announced today the appointment of Frank Kelly, Jr. to its Board of Directors. Mr. Kelly brings forty years of experience in finance, marketing and operations to InVasc.